Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | F7 | P08709 | 3/20 | 0.47 |
| ▸ | F3 | P13726 | 3/20 | 0.47 |
| ▸ | FABP3 | P05413 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | FABP4 | P15090 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | GNA15 | P30679 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2722282 | 0.80 | FFAR1 (0.57) | ALDH1A1KDM4EF7F3FABP3 | |
| SCHEMBL2621464 | 0.80 | TRPV1 (0.57) | ALDH1A1KDM4EF7F3FABP3 | |
| SCHEMBL15317873 | 0.80 | FFAR1 (0.57) | ALDH1A1KDM4EF7F3FABP3 | |
| SCHEMBL2722281 | 0.80 | FFAR1 (0.57) | ALDH1A1KDM4EF7F3FABP3 | |
| SCHEMBL12186743 | 0.80 | FFAR1 (0.57) | ALDH1A1KDM4EF7F3FABP3 | |
| SCHEMBL6037208 | 0.80 | FFAR1 (0.57) | ALDH1A1KDM4EF7F3FABP3 | |
| SCHEMBL21197439 | 0.80 | FFAR1 (0.57) | ALDH1A1KDM4EF7F3FABP3 | |
| SCHEMBL21197440 | 0.80 | FFAR1 (0.57) | ALDH1A1KDM4EF7F3FABP3 | |
| SCHEMBL20603893 | 0.80 | FFAR1 (0.57) | ALDH1A1KDM4EF7F3FABP3 | |
| SCHEMBL44603 | 0.80 | FFAR1 (0.57) | ALDH1A1KDM4EF7F3FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114949237-A | Vesicle | 斯昆申技术控股有限责任公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20210393655-A1 | Vesicular Formulations for Use in the Treatment of Pain or Reduced Mobility of a Joint | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2021-12-23 | — | — | US | disclosed |
| US-20150132349-A1 | Vesicular Formulations, Kits and Uses | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2015-05-14 | — | — | US | disclosed |
| US-20120177698-A1 | AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | CEVC GREGOR (DE) | 2012-07-12 | — | — | US | disclosed |
| US-20090155235-A1 | AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2009-06-18 | — | — | US | disclosed |
| US-20090060990-A1 | NSAID FORMULATIONS, BASED ON HIGHLY ADAPTABLE AGGREGATES, FOR IMPROVED TRANSPORT THROUGH BARRIERS AND TOPICAL DRUG DELIVERY | IDEA AG (DE) | 2009-03-05 | — | — | US | disclosed |
| US-20090060989-A1 | NSAID FORMULATIONS, BASED ON HIGHLY ADAPTABLE AGGREGATES, FOR IMPROVED TRANSPORT THROUGH BARRIERS AND TOPICAL DRUG DELIVERY | IDEA AG (DE) | 2009-03-05 | — | — | US | disclosed |
| US-20090042989-A1 | NSAID FORMULATIONS, BASED ON HIGHLY ADAPTABLE AGGREGATES, FOR IMPROVED TRANSPORT THROUGH BARRIERS AND TOPICAL DRUG DELIVERY | IDEA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-7473432-B2 | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery | IDEA AG (DE) | 2009-01-06 | — | — | US | disclosed |
| EP-1551370-B1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| EP-1829527-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | disclosed |
| EP-1829528-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | disclosed |
| EP-1815846-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | disclosed |
| US-20070031483-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CEVC GREGOR | 2007-02-08 | — | — | US | disclosed |
| EP-1551370-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2005-07-13 | — | — | EP | disclosed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | disclosed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | disclosed |
| US-20040071767-A1 | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery | IDEA AG (DE) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040071767-A1 | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery | SLC43A1, TRPV2, TRPA1 | ALDH1A1 3692/4885KDM4E 4780/4885F7 3094/4885 |
| US-20090060989-A1 | NSAID FORMULATIONS, BASED ON HIGHLY ADAPTABLE AGGREGATES, FOR IMPROVED TRANSPORT THROUGH BARRIERS AND TOPICAL DRUG DELIVERY | SLC43A1, TRPV2, TRPA1 | ALDH1A1 3692/4885KDM4E 4780/4885F7 3094/4885 |
| US-20070031483-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | ALDH1A1 2042/4885KDM4E 2732/4885F7 1256/4885 |
| US-20120177698-A1 | AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | CUTA, ABCG2, ABCB11 | ALDH1A1 2195/4885KDM4E 1985/4885F7 1980/4885 |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | ALDH1A1 2042/4885KDM4E 2732/4885F7 1256/4885 |
| US-20090042989-A1 | NSAID FORMULATIONS, BASED ON HIGHLY ADAPTABLE AGGREGATES, FOR IMPROVED TRANSPORT THROUGH BARRIERS AND TOPICAL DRUG DELIVERY | SLC43A1, TRPV2, TRPA1 | ALDH1A1 3692/4885KDM4E 4780/4885F7 3094/4885 |
| US-20090060990-A1 | NSAID FORMULATIONS, BASED ON HIGHLY ADAPTABLE AGGREGATES, FOR IMPROVED TRANSPORT THROUGH BARRIERS AND TOPICAL DRUG DELIVERY | SLC43A1, TRPV2, TRPA1 | ALDH1A1 3692/4885KDM4E 4780/4885F7 3094/4885 |
| US-20090155235-A1 | AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | CUTA, ABCG2, PIGS | ALDH1A1 1958/4885KDM4E 2669/4885F7 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.